Eibl, R. H.; Schneemann, M. Liquid Biopsy and Glioblastoma. Exploration of Targeted Anti-tumor Therapy, 2023, 4, 28–41. https://doi.org/10.37349/etat.2023.00121.
Eibl, R. H.; Schneemann, M. Liquid Biopsy and Glioblastoma. Exploration of Targeted Anti-tumor Therapy, 2023, 4, 28–41. https://doi.org/10.37349/etat.2023.00121.
Eibl, R. H.; Schneemann, M. Liquid Biopsy and Glioblastoma. Exploration of Targeted Anti-tumor Therapy, 2023, 4, 28–41. https://doi.org/10.37349/etat.2023.00121.
Eibl, R. H.; Schneemann, M. Liquid Biopsy and Glioblastoma. Exploration of Targeted Anti-tumor Therapy, 2023, 4, 28–41. https://doi.org/10.37349/etat.2023.00121.
Abstract
Glioblastoma is the most common and malignant primary brain tumor. Despite a century of research efforts, the survival of patients has not significantly improved. Currently, diagnosis is based on neuroimaging techniques followed by histopathological and molecular analysis of resected or biopsied tissue. A recent paradigm shift in diagnostics ranks the molecular analysis of tissue samples as the new gold standard over classical histopathology, thus correlating better with the biological behavior of glioblastoma and clinical prediction, especially when a tumor lacks the typical hallmarks for glioblastoma. Liquid biopsy aims to detect and quantify tumor-derived content, such as nucleic acids (DNA/RNA), circulating tumor cells (CTC), or extracellular vesicles (EV) in biofluids, mainly blood, cerebrospinal fluid (CSF), or urine. Liquid biopsy has the potential to overcome the limitations of both neuroimaging and tissue-based methods to identify early recurrence and to differentiate tumor progression from pseudoprogression, without the risks of repeated surgical biopsies. This review highlights the origins and time-frame of liquid biopsy in glioblastoma and points to recent developments, limitations and challenges of adding liquid biopsy to support the clinical management of glioblastoma patients.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Commenter:
The commenter has declared there is no conflict of interests.
https://doi.org/10.37349/etat.2023.00121
Unfortunately, neither preprints, nor the publishing journal were really able to help to update it.